Acute Myeloid Leukemia

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Blasts 10 Percent or More of Bone Marrow Nucleated Cells

High Risk Myelodysplastic Syndrome

Myeloid Sarcoma

Myeloproliferative Neoplasm

Philadelphia Chromosome Positive

Cladribine

Cytarabine

Dexrazoxane Hydrochloride

Gemtuzumab Ozogamicin

Idarubicin

M D Anderson Cancer Center

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms

Will assess a decrease in LVEF of 10 percent from baseline or decrease in LVEF below the normal limit of 50% during treatment with dexrazoxane hydrochloride combined with cladribine, idarubicin, cytarabine, and gemtuzumab ozogamicin.

Cardiac symptoms to be evaluated include: clinical heart failure, exertional dyspnea, orthopnea, S3 gallop, acute coronary syndrome, acute pulmonary edema and life-threatening arrhythmias

Troponin levels will be collected before and after the day 1 dose of idarubicin each month during induction, consolidation, and maintenance therapy.

The recurrence-free survival rate at 6 months will be a binary endpoint where the recurrence including death occurred within 6 months of treatment will be considered as "recurrence event".

Metal chelation effects assessed by utilizing technologies commonly used in the geochemistry.

Will explore the impact of MRD on relapse.

M.D. Anderson Cancer Center

National Cancer Institute (NCI)

10 patients with hemochromatosis treated with Deferasirox

10 patients with hemochromatosis treated with venesection

20 patients with myelodysplastic syndrome treated with Deferasirox

10 healthy control persons to assess the normal level of investigational blood tests.

Hemochromatosis

Myelodysplastic Syndromes

Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months

Deferasirox

Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.

Venesection

Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.

Haukeland University Hospital, Clinical Trial Unit

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers.

myelodysplastic syndromes/набряк

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

Найповніша база даних про лікарські трави, підкріплена наукою